房水VEGF水平与新生血管性年龄相关性黄斑变性临床活动度的相关性
本研究纳入64例接受玻璃体腔雷珠单抗注射并随访12个月的新生血管性年龄相关性黄斑变性患者,采用酶联免疫吸附试验检测首次注射前房水VEGF水平。结果显示,负荷治疗后复发眼及负荷治疗后3个月内复发眼的基线房水VEGF水平均显著高于对照眼,提示治疗前房水VEGF水平与复发可能性显著相关。
要点
- 治疗前房水VEGF水平较高的眼在负荷治疗后更易复发。
- 负荷治疗后3个月内复发眼的基线房水VEGF水平显著更高。
- 检测治疗前房水VEGF水平可能有助于制定个体化治疗方案。
核心结论
- 治疗前房水VEGF水平与新生血管性年龄相关性黄斑变性负荷治疗后复发的可能性显著相关。
研究设计与样本
- 纳入接受玻璃体腔雷珠单抗注射治疗并随访12个月的新生血管性年龄相关性黄斑变性患者,共64例64眼。
- 治疗方案为连续3次每月玻璃体腔雷珠单抗注射(负荷治疗)后按需(PRN)治疗。
- 采用酶联免疫吸附试验检测首次玻璃体腔雷珠单抗注射前房水样本的VEGF水平。
主要发现
- 12个月内平均玻璃体腔雷珠单抗注射次数为4.6±1.4次,17眼在负荷治疗后无复发。
- 负荷治疗后复发眼平均房水VEGF水平显著高于无复发眼(107.6 vs. 83.8 pg/mL,P=0.04)。
- 负荷治疗后3个月内复发眼平均房水VEGF水平显著高于其他眼(114.9 vs. 86.7 pg/mL,P<0.01)。
临床怎么用
- 治疗前检测房水VEGF水平可能有助于判断新生血管性年龄相关性黄斑变性患者负荷治疗后的复发风险。
- 治疗前房水VEGF水平可能为制定个体化治疗选项提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of the current study was to investigate the correlation between the pretreatment aqueous level of vascular endothelial growth factor (VEGF) and clinical activity in neovascular age-related macular degeneration. METHODS: Patients with neovascular age-related macular degeneration treated by intravitreal ranibizumab injections and followed for 12 months were included in the current study. The treatment regimen consisted of three consecutive monthly intravitreal ranibizumab injections (loading treatment) followed by a pro re nata (PRN) treatment regimen. The aqueous VEGF levels were measured by enzyme-linked immunosorbent assay using aqueous humor samples obtained just before the first intravitreal ranibizumab injections. RESULTS: Sixty-four eyes of 64 patients were included in the current study. The mean number of intravitreal ranibizumab injections during 12 months was 4.6 ± 1.4, and 17 eyes had no recurrence after loading treatment. The mean aqueous VEGF level was significantly higher in eyes with recurrence after loading treatment than in eyes without recurrence (107.6 vs. 83.8 pg/mL, respectively; P = 0.04) and significantly higher in eyes with recurrence within 3 months after loading treatment than in other eyes (114.9 vs. 86.7 pg/mL, respectively; P < 0.01). CONCLUSION: Pretreatment aqueous VEGF level was significantly correlated with the likelihood of recurrence in neovascular age-related macular degeneration. The measurement of pretreatment aqueous VEGF level may be useful to determine the best treatment options for patients with neovascular age-related macular degeneration.
引用
- Ichiyama Y, Sawada T, Sawada O, et al. THE CORRELATION BETWEEN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AND CLINICAL ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2021. PMID: 32134804. doi:10.1097/IAE.0000000000002790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。